Key points are not available for this paper at this time.
This Viewpoint describes the FDA’s guidance on digital tools that seeks to balance technological innovation with assurances that medical mobile apps and other devices that fall within the agency’s regulatory purview are safe and effective.
Shuren et al. (Mon,) studied this question.